Heron Therapeutics, Inc. (0J4V.L)
USD 2.4
(0.42%)
USD 2.4
(0.42%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 120.65 Million USD | -45.66% |
| 2022 | 222.05 Million USD | -13.45% |
| 2021 | 256.55 Million USD | -8.57% |
| 2020 | 280.61 Million USD | -4.89% |
| 2019 | 295.04 Million USD | 26.14% |
| 2018 | 233.89 Million USD | 6.83% |
| 2017 | 218.93 Million USD | 34.1% |
| 2016 | 163.26 Million USD | 69.72% |
| 2015 | 96.19 Million USD | 365.82% |
| 2014 | 20.65 Million USD | -12.28% |
| 2013 | 23.54 Million USD | 141.45% |
| 2012 | 9.75 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 31.02 Million USD | -10.25% |
| 2024 Q2 | 31.39 Million USD | 1.21% |
| 2023 Q1 | 45.82 Million USD | 21.37% |
| 2023 Q3 | 38.15 Million USD | -29.35% |
| 2023 Q4 | 34.56 Million USD | -9.4% |
| 2023 FY | 172.55 Million USD | -22.29% |
| 2023 Q2 | 54 Million USD | 17.86% |
| 2022 FY | 222.05 Million USD | -13.45% |
| 2022 Q3 | 53.72 Million USD | -11.86% |
| 2022 Q2 | 60.95 Million USD | -18.76% |
| 2022 Q1 | 75.02 Million USD | 21.69% |
| 2022 Q4 | 37.75 Million USD | -29.72% |
| 2021 Q4 | 61.65 Million USD | -3.04% |
| 2021 Q2 | 68.39 Million USD | 8.68% |
| 2021 Q3 | 63.58 Million USD | -7.02% |
| 2021 FY | 256.55 Million USD | -8.57% |
| 2021 Q1 | 62.92 Million USD | 90.84% |
| 2020 Q3 | 21.44 Million USD | -12.3% |
| 2020 Q4 | 32.97 Million USD | 53.78% |
| 2020 FY | 280.61 Million USD | -4.89% |
| 2020 Q1 | 29.16 Million USD | -17.71% |
| 2020 Q2 | 24.44 Million USD | -16.16% |
| 2019 Q1 | 36.38 Million USD | 7.21% |
| 2019 Q2 | 31.46 Million USD | -13.5% |
| 2019 Q4 | 35.43 Million USD | 47.56% |
| 2019 FY | 295.04 Million USD | 26.14% |
| 2019 Q3 | 24.01 Million USD | -23.68% |
| 2018 FY | 233.89 Million USD | 6.83% |
| 2018 Q4 | 33.93 Million USD | 71.94% |
| 2018 Q3 | 19.73 Million USD | -0.11% |
| 2018 Q2 | 19.75 Million USD | -2.86% |
| 2018 Q1 | 20.33 Million USD | -13.31% |
| 2017 FY | 218.93 Million USD | 34.1% |
| 2017 Q2 | 20.59 Million USD | 13.86% |
| 2017 Q3 | 19.84 Million USD | -3.67% |
| 2017 Q4 | 23.46 Million USD | 18.23% |
| 2017 Q1 | 18.09 Million USD | -20.13% |
| 2016 Q3 | 17.49 Million USD | 10.85% |
| 2016 FY | 163.26 Million USD | 69.72% |
| 2016 Q2 | 15.78 Million USD | -8.36% |
| 2016 Q1 | 17.22 Million USD | 17.18% |
| 2016 Q4 | 22.65 Million USD | 29.49% |
| 2015 FY | 96.19 Million USD | 365.82% |
| 2015 Q4 | 14.69 Million USD | 78.53% |
| 2015 Q1 | 5.85 Million USD | -26.05% |
| 2015 Q3 | 8.23 Million USD | 20.35% |
| 2015 Q2 | 6.83 Million USD | 16.79% |
| 2014 Q2 | 4.65 Million USD | -18.26% |
| 2014 Q3 | 4.23 Million USD | -8.92% |
| 2014 FY | 20.65 Million USD | -12.28% |
| 2014 Q1 | 5.69 Million USD | -19.52% |
| 2014 Q4 | 7.91 Million USD | 86.81% |
| 2013 FY | 23.54 Million USD | 141.45% |
| 2013 Q4 | 7.07 Million USD | 9.72% |
| 2013 Q1 | 5.61 Million USD | 61.45% |
| 2013 Q3 | 6.44 Million USD | 46.45% |
| 2013 Q2 | 4.4 Million USD | -21.54% |
| 2012 Q4 | 3.47 Million USD | 0.0% |
| 2012 FY | 9.75 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Editas Medicine, Inc. | 247.3 Million USD | 51.211% |
| Dynavax Technologies Corporation | 219.14 Million USD | 44.942% |
| Cara Therapeutics, Inc. | 142.46 Million USD | 15.306% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 99.703% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 77.192% |
| Perrigo Company plc | 1.52 Billion USD | 92.106% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 56.235% |
| Illumina, Inc. | 3.81 Billion USD | 96.836% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 98.823% |
| Nektar Therapeutics | 190.9 Million USD | 36.797% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 73.246% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 94.123% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -170.126% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 93.091% |
| Waters Corporation | 943.51 Million USD | 87.212% |
| Biogen Inc. | 5.2 Billion USD | 97.682% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | 47.238% |
| Adicet Bio, Inc. | 152.03 Million USD | 20.64% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 94.295% |
| Homology Medicines, Inc. | 9.87 Million USD | -1121.843% |
| Geron Corporation | 70.44 Million USD | -71.288% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 93.297% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 71.786% |
| Myriad Genetics, Inc. | 600.1 Million USD | 79.894% |
| Evolus, Inc. | 189.75 Million USD | 36.416% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -116.402% |
| bluebird bio, Inc. | 240.23 Million USD | 49.775% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 78.125% |
| Zoetis Inc. | 2.76 Billion USD | 95.636% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -148.767% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -893.798% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 88.924% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 97.473% |
| uniQure N.V. | 285.08 Million USD | 57.677% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -208.168% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 84.523% |
| Verastem, Inc. | 92.08 Million USD | -31.029% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 55.624% |
| FibroGen, Inc. | 398.11 Million USD | 69.693% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 91.133% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -767.434% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 92.442% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 95.714% |
| OPKO Health, Inc. | 574.68 Million USD | 79.005% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -19.667% |
| Exelixis, Inc. | 1.58 Billion USD | 92.396% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 59.689% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 74.671% |
| Imunon, Inc. | 21.03 Million USD | -473.726% |
| Blueprint Medicines Corporation | 722.86 Million USD | 83.308% |
| Insmed Incorporated | 949.26 Million USD | 87.289% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 70.486% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 67.267% |
| TG Therapeutics, Inc. | 198.47 Million USD | 39.208% |
| Incyte Corporation | 1.19 Billion USD | 89.865% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 88.443% |